Daily Stock List
BreedIT Corp. (BRDT)
SmallCapVoice and PennyStocks Forever reported earlier on BreedIT Corp. (BRDT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Founded in 2013, BreedIT Corp., by way of its Israeli subsidiary, BreedIT Ltd., is the developer of highly sophisticated agro-breeding solutions for plant breeders and researchers. The Company’s proven iBreedIT® - the Intelligent Decision Support System (IDSS) for breeders was developed by a team consisting of among the world's top breeding specialists for optimizing the breeding processes. iBreedIT® services the plant breeding needs of corporations, research, as well as government institutions. BreedIT has offices in New York, New York, and Rehovot, Israel.
BreedIT’s IDSS provides advanced solutions for generating and disseminating knowledge. This is targeted at helping breeders to plan, manage, and analyze their breeding data and to perform research activities quickly and effectively. Breeders can buy a SaaS (Software as a Service) license for the proprietary iBreedIT platform.
BreedIT is a foremost provider of software designed to help breeders modify crops to emphasize specific traits. Through its subsidiary BreedIT Ltd., it has teamed up with Seach Ltd. - one of only eight entities licensed to grow and distribute medical cannabis in Israel - to form KanaboSeed.
KanaboSeed works to discover, develop, and also commercialize new cannabis strains for the management of an array of diseases and conditions. Seach Ltd. will initially be growing the KanaboSeed strains. However, the long-term plan for the business model comes from possible license agreements with medical cannabis growers interested in the proprietary genetics.
In January 2015, BreedIT, via its Israeli subsidiary, BreedIT Ltd., announced that it entered into a pilot agreement for its BreedIT Mobile™ with Vilmorin & Cie. The BreedIT Mobile™ is a cloud-based service and mobile application. The design of it is to help breeders and growers be more efficient in the field and other remote locations.
BreedIT Ltd. will integrate the mobile platform to work with the Synergene Seed systems already being used by Vilmorin's Ha'zera and HM-Clause business units. The BreedIT Mobile™ enables breeders to employ tablets and smartphones to collect plant phenotypes and other information essential to the breeding process.
BreedIT Corp. (BRDT), closed Friday's trading session at $0.034, up 3.03%, on 2,007 volume with 2 trades. The average volume for the last 60 days is 82,438 and the stock's 52-week low/high is $0.03/$0.494.
Bluesphere Corp. (BLSP)
OTC Stock Review, PennyStocks24, OTPicks, Penny Stock General, Fast Money Alerts, Stock Shock and Awe, MyBestStockAlerts, SmallCapVoice, and PremiereStockAlerts reported on Bluesphere Corp. (BLSP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Bluesphere Corp. is working to become an important player in the global waste-to-energy and renewable energy markets. Fundamentally, the Company is a waste-to-energy project integrator. A clean energy company, it has a business plan that fits the changing regulatory standards for waste and energy. The Company’s primary business model is BOO (Build-Own-Operate): long-term energy agreements are executed with electric companies in advance of projects.
Bluesphere is an international business that develops, manages, and owns waste-to-energy projects. The Company is performing waste-to-energy projects in the United States and West Africa. It is presently centering on projects for which it has signed agreements, term sheets or memoranda to own and implement such projects and which are in various stages of development.
In the U.S., it has its Charlotte, North Carolina Waste to Energy Anaerobic Digester 5.2 MW Plant. In Johnston, Rhode Island, it has its Waste to Energy Anaerobic Digester 3.2 MW Plant. In Africa, it has its Ghana Oblogo – Landfill project. Bluesphere established a company, Pure Sphere, which is owned 50 percent by Bluesphere and 50 percent by Bpure, for the implementation of the project in Ghana. The project consists of the installation of a gas collection system and flare at two closed landfills in Ghana.
Bluesphere is pursuing a strategy to work in association with landfill owners to convert harmful methane gas emissions from landfills into electricity. The process is based on readily available technology already being used in different parts of the U.S. and other regions globally. In addition, it has signed a Memorandum of Understanding (MOU) to develop a 5 MW biogas project together with ESC an Israeli State-owned company in Israel. This marks the start of Bluesphere's Israeli Strategy and its first project in the nation.
Bluesphere’s technology division has acquired the rights for "fast charge battery" technology. The new technology provides the solution in all three consumer concerns (safety, charging, and lifecycle) as it is expected to recharge 70 percent in 2 minutes and increase the life cycle from 2-3 years to more than 20 years.
Bluesphere is now past the initial stage of evaluating certain projects for acquisition or development. These projects include nine more 1 MW facilities in Italy with at least one year of operating history; many landfill gas to energy projects in the U.S.; many anaerobic digestion projects in the U.S. and Canada; and 10 renewable natural gas projects in the U.S. It is evaluating acquisition, development and/or participation in approximately $500 million in organics to energy projects in the U.S., Canada and worldwide.
Last week, Blue Sphere announced that it acquired 4 fully operational biogas facilities in Italy. Each of these facilities produce 1MW. On Thursday, May 28, 2015, Bluesphere broke ground on its waste to energy project in Johnston, Rhode Island.
Bluesphere Corp. (BLSP), closed Friday's trading session at $0.041, up 7.33%, on 504,507 volume with 23 trades. The average volume for the last 60 days is 763,291 and the stock's 52-week low/high is $0.0351/$0.35.
Green Technology Solutions, Inc. (GTSO)
SmallCapVoice and PennyStocks24 reported earlier on Green Technology Solutions, Inc. (GTSO), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Green Technology Solutions, Inc. provides business support, delivery system products, and horticultural technology support. A cannabis technology innovator, the Company explores the fast-growing cannabis market for resources. This includes, but is not limited to, rare earth elements, precious metals, and herbal supplements. Its objective is to support the medical cannabis industry with unique products, services, and processes. Green Technology Solutions is headquartered in San Jose, California.
Green Technology Solutions believes it can help in providing a safe and secure environment for the dispensing of medical marijuana and much-needed payment options to give patients easy access to the medicine they require. It works to facilitate the process for patients to get the care they need from their practitioners and eliminate variables that affect the quality of that care.
The Company’s focus on horticultural technology development enables cannabis growers to prosper and patients to receive the quality care they need. The technology includes specialty organic soils and fertilizers storage, growth, and lighting systems, and methods for producing other cannabinoid products. Its development projects aspire to lessen costs for growers and increase the consistency and potency of their product.
Regarding horticultural technology support, streamlining the growing process provides a more consistent and better quality product for consumers. Pertaining to health & wellness, delivery system products, capsules, topical treatments, vapor inhalants, and drinks undergoing development will enable easier access to medication.
Green Technology Solutions has purchased emerging horticultural innovator Mother Parker’s Soil. This company employs the latest technologies in soil preparation to provide consumers the highest-quality organic-based products.
This month, Green Technology Solutions and its joint venture (JV) partner, Elevated Industries, announced that they are preparing four different treats for the billion-dollar U.S. cannabis edibles market. The Company created a JV with innovative cannabis edibles developer Elevated Industries in 2014 to deliver new products tailored to increasingly sophisticated cannabis businesses and consumers in Colorado and beyond. Currently, the debut suite of products to be developed and marketed by the JV is close to being ready for retailers.
Green Technology Solutions, Inc. (GTSO), closed Friday's trading session at $0.34, up 9.71%, on 78,259 volume with 36 trades. The average volume for the last 60 days is 76,351 and the stock's 52-week low/high is $0.251/$11.00.
AmpliPhi Biosciences Corp. (APHB)
Top Stock Picks reported recently on AmpliPhi Biosciences Corp. (APHB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
AmpliPhi Biosciences Corp. is a biotechnology company and the worldwide leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections. The Company’s product development programs target infections, which are frequently resistant to existing antibiotic treatments. AmpliPhi Biosciences is based in Richmond, Virginia. The Company has operations outside Sydney, Australia.
AmpliPhi Biosciences concentrates on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Bacteriophages, or “eaters of bacteria,” are highly targeted viruses. They only infect bacteria. As they grow, numerous bacteriophages destroy their bacterial host to release hundreds of new bacteriophages.
Phage-based therapy provides an innovative and proven approach to treating a broad variety of bacterial infections and more precisely, drug-resistant strains of bacteria that are typically found in hospitals. AmpliPhi Biosciences is the first company to demonstrate the clinical efficacy of phage technology in a controlled, regulated, human clinical trial.
The Company has focused initially on controlling one particular problem, namely “Pseudomonas aeruginosa” infections. Pseudomonas aeruginosa is a common soil organism. It is responsible for long-term problems in humans, infecting burns, wounds, and body cavities. Its product development pathway includes AmpliPhage-001: Lung Infections in Cystic Fibrosis (CF) Patients Caused by P. aeruginosa; AmpliPhage-002: Wound and Skin Infections Caused by S. aureus; and AmpliPhage-004; Gastrointestinal (GI) Infection Caused by C. difficile infection (CDI).
AmpliPhi Biosciences is working together with several top organizations to quickly advance bacteriophage-based therapies. These organizations include Intrexon Corp. (XON), the U.S. Army, and UK-based University of Leicester. AmpliPhi has a new and first-in-class GMP-ready bacteriophage production facility now fully operational in Slovenia.
AmpliPhi Biosciences continues to center on continuing strategic R&D initiatives with leading industry, academic, and government partners in Europe, Australia, and the U.S. At first, AmpliPhi’s phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.
AmpliPhi Biosciences has appointed industry veteran M. Scott Salka as its new Chief Executive Officer. The Company has been granted a European patent for proprietary bacteriophage preparations for use in combination with antibiotics for the treatment of biofilm related infections caused by the bacterium Pseudomonas aeruginosa. Moreover, AmpliPhi has continued its collaboration with Intrexon to focus on AmpliPhage-001 and AmpliPhage-004 (for Clostridium difficile).
Additionally, AmpliPhi has advanced plans to report nebulizer qualification study data from the AmpliPhage-001 program for treating Pseudomonas aeruginosa in mild to moderate cystic fibrosis patients at an upcoming scientific congress. Furthermore, the Company has furthered plans to start clinical trials at the Walter Reed Clinical Trial Center in the second half of this year for AmpliPhage-002, for treating multi-drug resistant strains of Staphylococcus aureus.
AmpliPhi Biosciences Corp. (APHB), closed Friday's trading session at $0.1621, down 2.35%, on 1,681,843 volume with 21 trades. The average volume for the last 60 days is 2,164,570 and the stock's 52-week low/high is $0.0013/$0.5882.
Applied Minerals, Inc. (AMNL)
Real Pennies reported previously on Applied Minerals, Inc. (AMNL), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Applied Minerals, Inc., through its ownership of the historic Dragon Mine deposit, is the leading global source of Halloysite Clay and related technology solutions. The Company markets its products under the Dragonite™ trade name. It is the leading producer of Halloysite clay and advanced natural iron oxide solutions from its wholly-owned Dragon Mine property in Utah. Its products address the worldwide need for high performance, eco-friendly solutions for an array of industrial applications. Applied Minerals is based in New York, New York.
Halloysite is an aluminosilicate clay. It exhibits a rare, naturally occurring hollow tubular structure. Halloysite tubes have a length in the range of 0.5 - 3.0 microns, an exterior diameter in the range of 50 - 70 nanometers, and an internal diameter (lumen) in the range of 15 - 30 nanometers.
Applied Minerals serves the traditional halloysite markets for use in technical ceramics and catalytic applications. In addition, the Company has developed niche applications that benefit from the tubular morphology of its halloysite. These applications include carriers of active ingredients in paints, coatings and building materials, environmental remediation, agricultural applications and high-performance additives & fillers for plastic composites.
Applied Minerals’ Dragonite™ is a versatile Halloysite product grade. It has a wide variety of applications. Its Dragonite-XR™ product grade offers unique advantages in comparison to other reinforcing fillers, including glass fiber, mica, wollastonite or talc. It is an advanced reinforcing filler.
Applied Minerals’ Dragonite-HP™ is a high performance additive for engineering thermoplastics used at loadings of only 1-3 percent. It provides premier mechanical performance and cycle time reduction. Furthermore, the Company’s Dragonite-PureWhite™ is the highest purity Dragonite™ product. It meets the strict specifications of the cosmetic industry.
Regarding Iron Oxide products, Applied Minerals offers AMIRON. This is an advanced natural iron oxide for an assortment of pigmentary and technical applications. The Company launched its AMIRON line of advanced natural iron oxide pigments to the construction, wood coatings, paints, industrial coatings, plastics and rubber markets last year.
Applied Minerals’ recently indicated that Dragonite continues to attract considerable interest from adhesive, epoxy, and thermoset manufacturers as an all-natural, high value additive. It estimates the size of the global adhesives market alone to be around 9.4 million tons per annum. This presents a major volume opportunity for Dragonite even at low loading rates.
Applied Minerals, Inc. (AMNL), closed Friday's trading session at $0.65, up 3.17%, on 77,100 volume with 19 trades. The average volume for the last 60 days is 30,632 and the stock's 52-week low/high is $0.521/$0.865.
Pure Hospitality Solutions, Inc. (PNOW)
The QualityStocks Daily Newsletter would like to spotlight Pure Hospitality Solutions, Inc. (PNOW). Today, Pure Hospitality Solutions, Inc. closed trading at $0.0028, up 27.27%, on 1,681,843 volume with 21 trades. The stock’s average daily volume over the past 60 days is 2,164,570, and its 52-week low/high is $0.0013/$0.5882.
Pure Hospitality Solutions, Inc. announced today, that the Company nears completion of first quarter filings with the OTC Markets. It is expected that the process will be completed within the next 5 business days, as the Company's accountants wrap up the financial reports. Melvin Pereira, President and CEO of Pure Hospitality Solutions, Inc. further stated that, "As with the Year-End, this filing was temporarily delayed due to the implementation of our multi-million dollar divestiture initiative, where we again, successfully reduced an additional $1,000,000 of debt," and that "As PURE nears completion of first quarter filings, and our programming team aggressively ramps up the coding integration of Oveedia, we find ourselves at a truly remarkable place as a Company."
Pure Hospitality Solutions, Inc. (PNOW) is a provider of proprietary technology, marketing solutions, infrastructure and branding services to hotel operators.
The company's innovative platform functions as a powerful vehicle to help hotel operators achieve greater success in three specific areas: (i) expanded international exposure and recognition, (ii) powerful core structure, and (iii) high occupancy rates that drive increases in bottom-line profits. Pure continuously refines its suite of proprietary solutions to deliver measurable and proven results to hotel properties. This success has been reflected in those properties operating under the Hotel PURE brand as well as with independent boutique hotel properties utilizing the company's Friendly Reservation Online (FROL) booking engine technology and internet marketing services.
Operating a successful bi-lateral business model, Pure has four objectives:
1. To franchise the Hotel PURE brand to selected hotel properties worldwide similar to the business model currently employed by Big Brand operators such as Holiday Inn, Marriott, Sheraton and others;
2. Provide highly efficient and economical back-end booking engine technology services to independently branded boutique hotels that require a robust online presence;
3. Launch a stand-alone online hotel booking search engine primarily focused on Central America; and,
4. Expand the portfolio of Pure-owned boutique hotels operating under the Hotel PURE brand.
The company initially began growing its operations primarily in the United States. However most recently, major opportunities in Central America began presenting themselves, giving Oriens the ability to retool its business model. Now the company is positioned to acquire, own and operate its own properties – which would be marketed under the new brand with occupancies handled by the re-launched online booking engine system.
Ultimately, Pure intends to become a top-tier hotel brand operator and Internet booking and marketing service provider, qualifying as a preferred supplier to lending institutions. The company also intends to establish an invaluable international footprint with its online booking engine technology and marketing offerings; making that segment of its business a prime acquisition target for major online travel search and booking engine companies. Advancement toward this goal is guided by an executive management team with deep expertise in technology, banking, management, hospitality, branding and marketing, technical development and more. Disclaimer
Pure Hospitality Solutions, Inc. Company Blog
Pure Hospitality Solutions, Inc. News:
PURE Hospitality Solutions Nears Completion of First Quarter Filings
Pure Hospitality Solutions Teams up with Investors Hangout
Pure Hospitality Solutions Ramps Up Coding Integration
IFAN Financial, Inc. (IFAN)
The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.12, up 7.62%, on 37,329 volume with 17 trades. The stock’s average daily volume over the past 60 days is 61,900, and its 52-week low/high is $0.0114/$1.01.
IFAN Financial, Inc. was pleased to announce today that it has closed a funding agreement with NY-based Sea Otter Global Ventures, LLC, manager of SBI Investments, LLC (together, "Sea Otter") for $2,500,000. The financing is comprised of two parts -- a $500,000 secured promissory note and a $2,000,000 equity line of credit. The 12-month loan is secured by insider stock, and carries a 10% annual interest rate, payable quarterly in cash. Sea Otter provided half of the loan upon closing, and the other half will be released upon filing of the S-1 registration statement.
IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.
Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.
Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.
IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer
IFAN Financial, Inc. Company Blog
IFAN Financial, Inc. News:
IFAN Financial Announces $2.5 Million Financing by Sea Otter Global Ventures, LLC
IFAN Financial Applauds Facebook's Move Into the Mobile Payments Industry, Foresees Ancillary Opportunities
IFAN Financial Payment Gateway Adopted by Digital Branding Agency Blue Like Neon to Bolster Customers' eCommerce Capabilities
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $10.00, up 25.00%, on 6,110 volume with 12 trades. The stock’s average daily volume over the past 60 days is 238, and its 52-week low/high is $3.16/$15.00.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board
VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
Cleartronic, Inc. (CLRI)
The QualityStocks Daily Newsletter would like to spotlight Cleartronic, Inc. (CLRI). Today, Cleartronic, Inc. closed trading at $0.1399, up 12.10%, on 38,835 volume with 12 trades. The stock’s average daily volume over the past 60 days is 39,531, and its 52-week low/high is $0.04/$0.5499.
Cleartronic, Inc. (CLRI) is a technology holding company that creates and acquires operating subsidiaries to develop, manufacture and sell products, services and integrated systems to government agencies and business enterprises.
VoiceInterop, Inc., a wholly owned subsidiary, is a provider of patented IP communication gateways and communication software. Its gateways are marketed worldwide direct to customers as well as through a network of value added resellers. VoiceInterop has also developed an interoperable communication solution for use by airports. The company markets, installs and supports this interoperability solution directly to airports. International airports currently using the VoiceInterop communication solution include Dulles, Reagan, Omaha, Cincinnati, Green Bay and West Palm Beach.
A recent license agreement provides Cleartronic with the right to market Collabria LLC’s revolutionary ReadyOp™ command, control and communication platform. ReadyOp is a web-based application that integrates multiple databases and a robust communications platform supporting day-to-day activities for planning and managing small- and large-scale events. ReadyOp is designed for fast, efficient access to information and for communication with multiple persons, groups and agencies. ReadyOp is currently being used by numerous federal, state and local government agencies and private enterprises.
Backed by a management team committed to growing its business and finding ways to create value for shareholders, Cleartronic is well-positioned to grow in a broad array of markets. The company has a solid business plan in place that maximizes available resources for accelerated growth and has proven its ability to identify strong business opportunities. Disclaimer
Cleartronic, Inc. Company Blog
Cleartronic, Inc. News:
Cleartronic, Inc. (CLRI) Subsidiary Signs Agreement with Houston-Galveston Area Council
Cleartronic, Inc. (CLRI) on the "Your Monies Worth" Show
Cleartronic, Inc. (CLRI) to Be Featured on National Radio Show And Web-TV
Growblox Sciences, Inc. (GBLX)
The QualityStocks Daily Newsletter would like to spotlight Growblox Sciences, Inc. (GBLX). Today, Growblox Sciences, Inc. closed trading at $0.39, up 2.63%, on 67,309 volume with 33 trades. The stock’s average daily volume over the past 60 days is 63,990, and its 52-week low/high is $0.151/$3.49.
Growblox Sciences, Inc. (GBLX), a biopharmaceutical research and development company, is focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.
The company’s GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, and CureBLOX equipment. Together, these components provide unparalleled control and monitoring of cannabis cultivation throughout the plant's life-cycle. These patent pending processes were designed to produce a safe and consistent cannabis product under cGMP guidelines. Utilizing a computer-regulated system that optimizes the nutrients, water, temperature, and gas levels, the GrowBLOX suite produces cannabis with more active ingredients per pound than traditional cultivation methods.
Also, based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, Growblox Sciences has identified the most effective profiles of cannabinoids and terpenes for the treatment of conditions within seven therapeutic categories. As a result of this extensive research and the analysis of the active ingredient profiles of 30,000 Cannabis strains in conjunction with a major testing lab, the company will be able to provide patients with natural cannabis strains containing the ideal ratios for treating specific diseases or symptoms.
Another significant advantage held by the company stems from an accelerated drug development program to finish in 3-5 years instead of the 15-20 years typically seen in traditional pharmaceutical development programs. Armed with an intellectual property strategy that takes full advantage of the design of the GrowBLOX technology suite and protects the valuable foundation laid, Growblox Sciences has positioned itself well for long-term success in the burgeoning cannabis space. Disclaimer
Growblox Sciences, Inc. Company Blog
Growblox Sciences, Inc. News:
GrowBLOX Announces Deployment of Commercial Units
Growblox Sciences, Inc. (GBLX) is “One to Watch”
Growblox Announces Commercialization Initiative and Financing
Today's Top 3
NBT Equities Research
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Car Monkeys Group (CKMY) Announces Engagement of QualityStocks Investor Relations Services
- Cleartronic, Inc. (CLRI) Subsidiary Signs Agreement with Houston-Galveston Area Council
- Consorteum Holdings, Inc. (CSRH) Signs License Agreement With NYG Holdings
- Dominovas Energy Corp. (DNRG) Key Management Featured in Exclusive QualityStocks Interview
- Galenfeha, Inc. (GLFH) Completes Field Testing, Begins Production and Shipping of New Battery System
- Growblox Sciences, Inc. (GBLX) Announces Commercialization Initiative and Financing
- IFAN Financial, Inc. (IFAN) Announces $2.5 Million Financing by Sea Otter Global Ventures, LLC
- International Stem Cell Corp. (ISCO) to Present at International Society for Cellular Therapy Annual Meeting
- MIT Holding, Inc. (MITD) Launches New Website with Investor Relations Suite
- Mobile Lads Corp. (MOBO) Begins Operating And Buys Control Of North American Shopping Network Simbadeals.com From DoMark International
- One World Holdings, Inc. (OWOO) Raises Capital to Fund National Expansion and Convertible Note Elimination
- Pure Hospitality Solutions, Inc. (PNOW) Nears Completion of First Quarter Filings
- Save The World Air, Inc. (ZERO) Congratulates Pipeline Research Council International on New Technology Development Center
- Sibling Group Holdings, Inc. (SIBE) Urban Planet Mobile Deepens Strategic Partnership With Imagine Easy Solutions and EasyBib; UPMs Writing Planet Essay Scoring Solution to Be Offered Across All Imagine Easy Citation Websites Worldwide
- View Systems, Inc. (VSYM) Announces Engagement of QualityStocks Investor Relations Services
- VistaGen Therapeutics, Inc. (VSTA) and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
- Well Power Inc. (WPWR) Appoints Professional Engineer, Oil & Gas Veteran to Board of Directors